Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis

• DOI: 10.1111/apt.16730
• Publication Date: 2021-12-14T08:17:22Z
• Authors: Yousaf Hadi; Parambir S. Dulai; Justin Kupec; Nabeeha Mohy‐Ud‐Din; Vipul Jairath; Francis A. Farraye; Gursimran S. Kochhar
• Keywords: Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; SARS-CoV-2; Incidence; COVID-19; Humans; Inflammatory Bowel Diseases; Retrospective Studies; 3. Good health

Summary Background Accurate estimates for the risk of COVID‐19 in IBD, and an understanding impact on IBD course incident post‐infectious are needed. Aims To estimate study its IBD. Methods A retrospective propensity score matched cohort utilising multi‐institutional research network TriNetX. patients with without were identified to quantify outcomes disease course. The was compared population not infected during a similar time period. Results Incidence rate ratio lower non‐IBD (0.79, 95% CI: 0.72‐0.86). COVID‐19‐infected at increased requiring hospitalisation (RR: 1.17, 1.02‐1.34) no differences need mechanical ventilation or mortality. Patients steroids critical care 2.22, 1.29‐3.82). Up 7% suffered flare 3‐months post‐infection. Risk post‐COVID than that seen non‐COVID 0.64, 0.54‐0.65). Conclusion We observed increase amongst de novo after infection. confirmed prior observations regarding steroid use severity